



PATENT


Case Docket No. BIOBANK.009CP1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Girard, et al.  
Appl. No. : 10/601072  
Filed : June 19, 2003  
For : CHEMOKINE-BINDING  
PROTEIN AND METHODS OF  
USE  
Examiner : Unknown  
Group Art Unit : 1641

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

January 23, 2004  
(Date)

  
Jerry L. Hefner, Ph.D., Reg. No. 53,009


TRANSMITTAL LETTER


Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- ( X ) A Supplemental Information Disclosure Statement.
- ( X ) A PTO Form 1449 with twenty-six (26) references.
- ( X ) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- ( X ) Return prepaid postcard.

  
Jerry L. Hefner, Ph.D.  
Registration No. 53,009  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Applicant : Girard, et al.  
App. No. : 10/601072  
Filed : June 19, 2003  
For : CHEMOKINE-BINDING PROTEIN AND METHODS OF USE  
Examiner : Unknown  
Group Art Unit : 1641

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:


Enclosed is form PTO-1449 listing 26 references that are also enclosed.


This Supplemental Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: January 23, 2004

By:   
Jerry L. Hefner  
Registration No. 53,009  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. BIOBANK.009CP1	APPLICATION NO. 10/601072
	APPLICANT Girard, et al.	
	FILING DATE June 19, 2003	GROUP 1641

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
---------------------	-----------------	------	------	-------	----------	---------------------------------

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	1	WO 96/33730	10-31-96	PCT				
	2	WO 97/11714	4-3-97	PCT				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	3	Alcami, et al. 1998. Blockade of Chemokine Activity by a Soluble Chemokine Binding Protein from Vaccinia Virus, <i>The Journal of Immunology</i> , 160:624-633.
	4	Arufo, Alejandro, 1998. Expression of Proteins in Mammalian Cells Transient Expression of Proteins using COS cells, <i>Current Protocols in Molecular Biology</i> , 16.12.1-16.12.7
	5	Arufo, et al., 1991. CD62/P-Selectin Recognition of Myeloid and Tumor Cell Sulfatides, <i>Cell</i> , 67:35-44.
	6	Baggiolini, et al., 1997. Human Chemokines: An Update, <i>Annu. Rev. Immunol.</i> 15:675-705.
	7	Baggiolini, et al., 1998. Chemokines and leukocyte traffic, <i>Nature</i> , 392:565-568.
	8	Cook, et al., 1995. Requirement of MIP-1 $\alpha$ for an Inflammatory Response to Viral Infection, <i>Science</i> , 269:1583-1585.
	9	D'Souza, et al. 1996. Chemokines and HIV-1 second receptors, <i>Nature Medicine</i> , 2:1293-1300.
	10	Graham, et al. 1997. The T1/35kDa Family of Poxvirus-Secreted Proteins Bind Chemokines and Modulate Leukocyte Influx into Virus-Infected Tissue, <i>Virology</i> , 229:12-24.
	11	Heaney, et al. 1996. Soluble Cytokine Receptors, <i>Blood</i> , 87:847-857.
	12	Howard, et al. 1996. Chemokines: progress toward identifying molecular targets for therapeutic agents, <i>Tibtech</i> , 14:46-51.
	13	Lalani, et al. 1997. The Purified Myxoma Virus Gamma Interferon Receptor Homolog M-T7 Interacts with the Heparin-Binding Domains of Chemokines, <i>Journal of Virology</i> , 71:4356-4363.
	14	McMahan, et al. 1991. A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types, <i>The EMBO Journal</i> , 10:2821-2832.
	15	Premack, et al. 1996. Chemokine receptors: Gateways to inflammation and infection, <i>Nature Medicine</i> , 2:1174-1178.
	16	Proost, et al. 1996. The role of chemokines in inflammation, <i>Int J Clin Lab Res</i> , 26:211-223.
	17	Rollins, Barrett J. 1997. Chemokines, <i>Blood</i> , 90:909-928.
	18	Rose-John, et al. 1994. Soluble receptors for cytokines and growth factors: generation and biological function, <i>Biochem. J.</i> , 300:281-290.
	19	Sekido, et al. 1993. Prevention of lung reperfusion injury in rabbits by a monoclonal antibody against interleukin-8, <i>Nature</i> , 365:654-657.

EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. BIOBANK.009CP1	APPLICATION NO. 10/601072
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Girard, et al.	
		FILING DATE June 19, 2003	GROUP 1641

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	20	Seed, et al. 1987. Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure, <i>Proc Natl Acad. Sci. USA</i> , 84:3365-3369.
	21	Smith, et al. 1997. Poxvirus Genomes Encode a Secreted, Soluble Protein That Preferentially Inhibits $\beta$ Chemokine Activity yet Lacks Sequence Homology to Known Chemokine Receptors, <i>Virology</i> , 236:316-327.
	22	Upton, et al. 1992. Encoding of a Homolog of the IFN- $\gamma$ Receptor by Myxoma Virus, <i>Science</i> , 258:1369-1372.
	23	von Andrian, Ulrich H., 1996. Intravital Microscopy of the Peripheral Lymph Node Microcirculation in Mice, <i>Microcirculation</i> , 3:287-300.
	24	von Andrian, et al. 1998. <i>In Situ</i> Analysis of Lymphocyte Migration to Lymph Nodes, <i>Cell Adhesion and Communication</i> , 6:85-96.
	25	Walz, et al. 1990. Recognition by ELAM-1 of the Sialyl-Le <sup>x</sup> Determinant on Myeloid and Tumor Cells, <i>Science</i> , 250:1132-1135.
	26	Yoshie, et al. 1997. Novel lymphocyte-specific CC chemokines and their receptors, <i>Journal of Leukocyte Biology</i> , 62:634-644.

S:\DOCS\SGJ\SGJ-3539.DOC:gem011504

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	